白血病是造血干细胞的恶性肿瘤，该病在儿科恶性肿瘤的发病率中居首位。分子靶向抑制剂研究是高效抗肿瘤药物研发的重要途径。白介素2受体(IL-2R)在细胞因子网络调节中起关键作用。IL-2R及其下游信号分子缺陷可能是肿瘤免疫逃逸的重要原因，纠正这种缺陷可用于肿瘤治疗。IL-2R分为三个亚基，分别为α、β和γ链，各自介导不同的信号通路从而影响生命活动。因此同时阻断IL-2Rα、β和γ通路是肿瘤治疗的一种新思路。在前期研究工作中，应用细胞膜色谱（CMC）技术从天然产物塔斯品碱的系列衍生物中筛选发现了全新结构的具有抗肿瘤活性的衍生物TPD7。本课题将在体内和体外研究TPD7抗白血病作用及其机制，通过建立电化学技术与CMC模型研究TPD7与IL-2R的相互作用，在分子水平上研究TPD7对IL-2R信号通路的抑制作用，并通过尾静脉注射方式研究TPD7的体内抑瘤作用，为开发高效抗白血病药物奠定实验基础。

Leukemia is a malignant tumour of the hematopoietic stem cells, statistics found that the incidence of the disease in pediatric malignant tumors is in the first place. One of the important ways for antitumor innovative drug research is to look for molecular targeted inhibitors. Interleukin 2 receptor (IL-2R) plays a key role in regulation of cytokine network. The defects of IL-2R and its downstream signaling molecules may be important reasons of tumor immune escape, thus correcting the defects can be used in tumor therapy. IL-2R is divided into three subunits, alpha, beta, and gamma chain, respectively. Each subunit mediates different signaling pathways, and affects life activities together. Using a combination of IL-2Rα, IL-2Rβ and IL-2Rγ inhibitors to completely block the IL-2R pathway is a very potent therapy in tumor therapy. In the previous studies, with cell membrane chromatography we found that the taspine derivative TPD7 could against tumor. In this study, in vitro and in vivo experiments were used to study the effect and mechanism for TPD7 against leukemia. The electrochemical techniques and cell membrane chromatography method were established to determine whether TPD7 competitively inhibits binding of IL-2 to the IL-2R, and the underlying mechanism for TPD7 inhibition of leukemia growth was investigated. We further characterized the anticancer effects of TPD7 in vivo by tail vein injections. The aim of this study is to establish the foundation for finding the novel compound with effective anti- leukemia activity.